Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRADITiONAL study of once-daily trientine tetrahydrochloride as first-line treatment for Wilson's disease
CTR20262776Phase 3Active
- Sponsor
- Orphalan
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trientine hydrochloride, penicillamine in Wilson disease (WD), sponsored by Orphalan. Started Jul 2026; status: active.
02
Drugs
trientine hydrochloridepenicillamine
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on CTR20262776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262776.